奥扎格雷联合依达拉奉对老年脑梗死患者脑水肿及神经功能的影响

Effects of ozagrel combined with edaravone on cerebral edema and neurological function in elderly patients with cerebral infarction

目的研究奥扎格雷联合依达拉奉对老年脑梗死患者脑水肿及神经功能的影响。方法选择2013年1月—2016年12月安康市中心医院的76例老年脑梗死患者,随机分为两组。对照组静脉滴注依达拉奉注射液治疗,每次30 mg,每天2次;观察组联合静脉滴注注射用奥扎格雷钠治疗,每次80 mg,每天1次。两组均持续治疗10 d。比较两组的临床治疗效果,ADL量表评分以及NIHSS量表评分,并于治疗后对两组采取颅脑CT复查,对患者的脑水肿程度进行分级评估。结果观察组的有效率为92.10%,显著高于对照组76.32%(P<0.05)。两组治疗10 d后的ADL量表评分显著升高(P<0.05),NIHSS量表评分显著降低(P<0.05),且观察组更为明显,差异有统计学意义(P<0.05)。观察组脑水肿分级为D级的发生率为5.26%,显著低于对照组的26.32%(P<0.05)。两组治疗后的血小板聚集率和血黏稠度均降低,且观察组显著低于对照组(P<0.05)。治疗后两组的最大峰值流速以及平均流速均显著升高(P<0.05),血管阻力指数以及搏动指数均显著降低(P<0.05),且观察组更为明显,差异有统计学意义(P<0.05)。结论奥扎格雷联合依达拉奉对老年脑梗死患者明显优于单纯使用依达拉奉,可以有效改善患者的日常生活能力和神经功能,缓解脑水肿,且用药安全性较高,对患者的预后具有积极作用。

Objective To investigate the clinical effect ofozagrel combined with edaravone on cerebral edema and neurological function in elderly patients with cerebral infarction.Methods Selected76 cases of patients with cerebral infarction who were treated in our hospital from January 2013toDecember 2016, divided into two groupsrandomly. The control group was treated with intravenous injection of edaravone, and the observation group was treated with intravenous infusion of ozagrel. The clinical treatment effect, ADL scale score and NIHSS scale score were compared between the two groups, and the brain edema degree of patients in the two groups was evaluated by CT examination after treatment. Results After treatment, the effective rate of the observation group was 92.10% (35/38), higher than that of the control group 76.32% (29/38) (P<0.05); the scores of ADL scale in the two groups were significantly increased (P<0.05), and the NIHSS scale score was significantly lower (P<0.05), and the observation group was significantly better than that of the control group (P<0.05). The incidence of cerebral edema grade D in the observation group was 5.26% (2/38), lower than control group 26.32% (10/38) (P<0.05); after treatment, the platelet aggregation rate and blood viscosity of the two groups were significantly decreased (P<0.05), and the decrease in the observation group was more obvious (P<0.05); after treatment, the maximum peak velocity and average flow rate of the two groups were significantly increased (P<0.05), the vascular resistance index and pulsatility index were significantly decreased (P<0.05), and the observation group was more obvious (P<0.05). Conclusion Edaravone combined with ozagrel in elderly patients with cerebral infarction is superior to the single use of edaravone can effectively improve the ability of daily life of patients and nerve function, relieve cerebral edema, and the safety is high, has a positive effect on the prognosis of the patients.